aap

110% LOQTEQ® sales growth in Q3, total sales increase by 20% to EUR 7.6 million - Seite 2

In the area of biomaterials, third-quarter sales growth of 21% to EUR 4.0 million, not accounting for project income, continued the good trend for the 2014 financial year. This area reported growth of 39% to EUR 12.5 million in total for the nine-month period.
  

Sales in EUR million	Q3/2014	Q3/2013	Change
Trauma   thereof LOQTEQ®	3.3 (2.4)	2.2 (1.1)	48% (110%)
Biomaterials	4.0	3.3	21%
Projects	0.1	0.5	-84%
Other	0.2	0.3	-25%
Sales from continued operations	7.6	6.3	20%

  

Sales in EUR million	9m/2014	9m/2013	Change
Trauma   thereof LOQTEQ®	8.4 (5.3)	6.5 (3.1)	29% (68%)
Biomaterials	12.5	9.0	39%
Projects	0.3	2.4	-89%
Other	0.7	1.1	-34%
Sales from continued operations	21.8	19.0	15%
Sales from discontinued operations	1.0*	9.4*²	-90%
Sales total	22.8	28.4	-20%

*  Sales revenues EMCM B.V. 01-02/2014: EUR 1.2 million less consolidation effects (EUR 0.2 million)
*² Sales revenues EMCM B.V. 01-09/2013: EUR 10.1 million less consolidation effects (EUR 0.7 million)

The dynamics of growth in the third quarter and in the first nine months of 2014 clearly underline aap's strategic alignment to the trauma area in which our IP-protected LOQTEQ® system is our current flagship product with which we were able to achieve growth rates of over 100% in the third quarter. The notice of allowance received at the beginning of October from the United States Patent and Trademark Office (USPTO) is a further important milestone and will support the market rollout in the United States in particular. 

__________________________

About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.